Orchestra BioMed Holdings (OBIO) Income from Non-Controlling Interests (2021)

Orchestra BioMed Holdings (OBIO) reported Income from Non-Controlling Interests of -$92329.0 for Q2 2021.

Orchestra BioMed Holdings (OBIO) has 1 years of Income from Non-Controlling Interests data on file, last reported at -$92329.0 in Q2 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -13.75 Mn
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn -
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn -
10 Orchestra BioMed Holdings 245.24 Mn 255.02 Mn 78,000.00 -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2021 -92,329.00